Eikon Therapeutics, Inc.
For the period ended Aug 13, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 13, 2026 · Filed Aug 13, 2026
Use the contents to explore the available documents and sections.
EIKN$5.90+1.0%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · DRAFT
DRAFT
EIK1004: Presenting initial Phase 1/2 data in patients with advanced solid tumors on Friday, October 23 at ESMO.
EIK1005: Presenting initial Phase 1/2 data in patients with advanced solid tumors on Friday, October 23 at the ESMO Congress 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.